DYN 250117 12.50P (DYN250117P12500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

DYN250117P12500

Watchlist

0.15
-0.34-69.39%

15min DelayClose Jan 10 16:00 ET

0.20High0.10Low

Intraday

5D
Daily

News

Positive Outlook for Dyne Therapeutics as DYN-101 Shows Promising Clinical Results and Strategic Regulatory Advancements
TipRanksJan 11 10:39 ET
Dyne Therapeutics: Positive Phase 1/2 Trial Results for DYNE-101 Lead to Buy Rating and Overweight Stock Recommendation
TipRanksJan 11 10:37 ET · Ratings
Small U.S. Stocks Close Lower; Dyne Therapeutics Posts Biggest Loss
Dow JonesJan 10 16:20 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
BenzingaJan 10 16:06 ET
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Dow JonesJan 10 14:36 ET · Ratings
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?
BenzingaJan 10 13:40 ET

Comments

Spinee

Jul 15, 2024 02:41

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
$XPeng (XPEV.US)$ stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.
$QuantumScape (QS.US)$ stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen $VOLKSWAGEN A G (VWAGY.US)$ 's battery company PowerC...

Trytosaveabit

May 20, 2024 12:31

$Dyne Therapeutics (DYN.US)$ Looking like a nice market response to the news/update

Trytosaveabit

May 20, 2024 05:42

News

$Dyne Therapeutics (DYN.US)$ Dyne Therapeutics Announces New Clinical Data From ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
GlobeNewswire· 7 mins ago
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months -
- DYNE-101 Showed Improvement in Myotonia, Muscle Strength, ...

Meltyy

May 16, 2024 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Moomoo AI

Mar 25, 2024 06:38

John Cox's appointment, with his vast biotech industry and rare disease commercialization experience, is viewed positively for Dyne Therapeutics. His leadership is anticipated to enhance the company's clinical programs and pipeline, and build more capabilities as Dyne continues to create stakeholder value.

Press Release: Dyne Therapeutics Announces CEO Transition